Bothell, Wash.

Went public 03/07/01 at $7 per share

Filing Range: 7.0 million shares at $8 to $10

Offering Size: $63 million

Post Offering Valuation: $206.78 million

Shares Outstanding: 29.1 million shares

Underwriters: J.P. Morgan Chase & Co./CIBC World Markets/ Banc of America Securities LLC

Company Counsel: Venture Law Group

Manager Counsel: Cahill Gordon & Reindel

Auditor: Pricewaterhouse Coopers LLP

The Company:

Develops monoclonal antibody-based cancer therapeutics. The company specializes in testing a treatment for tumors associated with breast, prostate, lung, ovarian and colon cancers as well as completing animal trials on cancers of the blood.

Venture Backers:

Sofinnova Ventures

BA Venture Partners

OVP Venture Partners

Indosuez Ventures

Financing Rounds:

Number of Round Amt.

Round # Round Date Stage Investors ($ thousands)

1 01/01/1998 2 Early Stage 7250.0

2 04/01/1998 2 Early Stage 6750.0

3 12/22/1999 3 Expansion 32000.0


(Data in $ millions except EPS)



Total Revenues: $0.09

Net Income: (7.8)

EPS: ($2.54)